Introduction

S
moking worldwide is identified as the second leading risk factor for death from any cause, resulting in almost 6 million deaths each year. 1 It is predicted that tobacco related mortality could rise to more than 8.3 million deaths by 2030, although it could decline by 9% in high-income countries. 2 Since 1980, the estimated global prevalence of daily smokers has decreased, but because of the population growth, the number of smokers has increased significantly. 3 Therefore tobacco use continues to significantly influence global health patterns.
Strong evidence from vast number of studies worldwide show that tobacco smoking increases the risk of cancer, vascular and respiratory diseases, also has serious effects on reproductive health. 4 To be precise, tobacco use is globally responsible for 10% of all deaths from cardiovascular diseases, and 22% of all cancer deaths. 5 According to the Statistics Lithuania, 34% of men and 9% of women aged 15 and older identified themselves as daily smokers in 2014. 6 compared with 42 and 10%, respectively in 2005. 7 High mortality rates due to specifically smoking-related diseases in Lithuania 8 is a significant public health issue that requires adequate interventions.
One of the most important measures for ascertaining the impact of tobacco on health is the estimation of the mortality attributable to its use. 9, 10 Methodologies for calculating smoking attributable mortality (SAM) vary according to availability of data, but mainly there are three methods of estimating mortality attributable to tobacco use-prevalence based analysis in cohort studies, prevalence-based analysis in case control studies and smoking impact ratio (SIR) method. However, the most widely used are prevalence methods [9] [10] [11] considered to yield accurate and reliable SAM estimations. Moreover, there were attempts to compare the above mentioned methods by applying them to the same population and very similar estimates were obtained in all comparisons, thereby conferring validity of all these methods. 9, 12 The main objective of this study was to estimate the number of deaths and years of potential life lost (YPLL) attributable to smoking in Lithuania in 2013.
Methods
Calculation of SAM and YPLL
Different methods exist to calculate the smoking attributable fractions (SAFs), but the most often used formula was originally proposed by Levin in 1953 . 13 Countries where smoking prevalence data is available separately for current smokers and former smokers use the adaptation of Levin's formula suggested by Walter.
14 Using astthe latter version we calculated the SAF for each disease, gender and age group based on smoking prevalence and relative risks (RRs) of disease specific deaths for smoking by the following formula:
where p0, p1 and p2 represent the prevalence of non-smokers, smokers and former smokers, respectively. RR1 and RR2 refer to the risk of dying from any cause among smokers and former smokers respectively compared with a baseline population of nonsmokers. SAM was derived by multiplying all-cause mortality rates by SAF. After estimating SAM, we calculated the number of YPLL before 75 years of age attributable to cigarette smoking. Life expectancy data by age and gender were obtained from the Statistics Lithuania. 15 YPLL were calculated by multiplying the number of smoking attributable deaths (SADs) cases per cause of death and 5-year age stratum with the number of years resulting from the subtraction of the mean age of each 5-year age stratum from the age of 75 years.
Smoking prevalence and mortality data sources
The majority of SAM studies focus on adults aged 35 and older, and provide gender specific analysis separately. 16 Gender and age groups (35-54; 55-64; 65-74; 75+) specific prevalence rates of current, former and non-smokers were obtained from the 2005 Health Interview Survey carried out by the Statistics Lithuania. The household survey population consisted of 2 838,6 thousand permanent residents of the Republic of Lithuania aged 15 years and older, and the estimated sample consisted of 11 thousand respondents. The residents were selected from the Population Register applying a probabilistic sampling method. In total, 8996 (81.8%) persons participated in the survey. Smoking status data used in this survey was self-reported. A more accurate description of the methodology is provided in the 2005 Health Interview Survey report. 7 Gender-specific smoking prevalence for the above mentioned 4-age groups is provided in the 
Selection of smoking-related diseases and RRs
Smoking-related diseases and disease-specific RRs were obtained from the analyses of Cancer Prevention Study II (CPS-II) and updated analyses of the pooled contemporary cohort population published in The 2014 Surgeon General Report. 4 The CSP-II is the largest prospective study of smoking, disease and mortality in the USA with a cohort of 1.2 million Americans ! 30 years of age. 16 Various countries relied on US-based RRs. 17 Overall our study includes 26 diseases or disease categories that have a significant association between smoking and mortality risk, including deaths in fires caused by smoking.
Lag factor and sensitivity analyses for the estimation of SAM We applied 8 years lag for our calculations of the SAF and assumed the same latency time for all death causes related to tobacco. Most smoking-related diseases are known to have a latency period lasting from several years to several decades, 4 but lack of comprehensive prevalence data allowed us to use data referring to 2005.
We have used SIR method established by Peto et al. 18 for evaluating whether use of different SAF calculation methods could have significant increase or decrease of SAM in the sensitivity analysis. This evaluation is based on the assumption that current lung cancer mortality provides a better measure of the exposure of lifetime tobacco smoking than current smoking prevalence. Slightly different age groups (30-44; 45-59; 60-69; 70-79; !80) than in base case analysis were used. Disease specific RRs were also obtained from the analyses of the CPS-II. 19 Lung cancer mortality rates for smokers and never smokers were taken from the CPS II study published in the 'WHO global report: mortality attributable to tobacco'. 5 The detailed methodology and weaknesses of SIR method has been described elsewhere. 9, 11, 12, 18, 20 For instance, two major weaknesses most often emphasized in literature are constant worldwide lung cancer mortality rates among never smokers and the same latency for all death causes related to tobacco.
Results
In Lithuania smoking is the cause of one out of seven deaths, one out of 35 among female and one out of four among male deaths. In 2013, a total of 5771 deaths of individuals aged 35 years and older (5181 males and 590 females) were caused by smoking. In total 79.9% of all deaths due to smoking in 2013 were attributable to accounted for 12.8% of all premature YPLL (15.7% in men and 5.4% in women). More comprehensive estimates are presented in table 2. Two specific diagnoses accounted for 67.8% of SAM: ischaemic heart disease (2861 SADs) and lung cancer (1054 SADs).
A sensitivity analysis carried out using alternative SIR method estimated that there would be 4686 SADs (11.3% of total all-cause deaths in 2013), a number that is 18.8% lower (table 3) then the one estimated in base case analysis using prevalence based methodology. SAM is lower by 21.2% among male and higher by 2.7% among female.
Discussion
Using smoking prevalence based method 5771 SADs were identified accounting for 24.9% of all cause deaths in men and 2.8% in women.
Calculating more precise estimates of the causes of death is a regular challenge for research and policy making. Such estimations enable more detailed understanding of problems caused by smoking and provide evidence to initiate development of more adequate national health policies. All methods for calculating SAM have specific limitations and our study is no exception. Limitations of the prevalence-based analysis in cohort studies method have been elaborated in the US Surgeon General's Report 2004, 21 expert panel, 22 several other epidemiological studies and apply to this study as well.
First limitation specific to this study is related to definition of tobacco use. According to the World Health Organization recommendations, 16 it is best to define a smoker, as a person reporting to have smoked ! 100 cigarettes in a lifetime and who smokes cigarettes every day or some days at the time of the survey, a former smoker as a person who has smoked ! 100 cigarettes or more but does not currently smoke, a non-smoker as somebody who has never smoked 100 cigarettes during a lifetime. Since only very narrow series of questions related to smoking were included in the 2005 Health Interview Survey, it was impossible to fully utilize this definition. Smokers, non-smokers and former smokers were defined according to respondents' personal assessment of their current status. Inevitably this has some potential impact on the estimations.
The issue of over or underestimation of prevalence is also related to inclusion of various forms of exposure (e.g. active and secondhand smoking, alternative means of tobacco smoking). Tobacco smoking in other forms than cigarettes is not very common in Lithuania, even though for identifying smokers the 2005 Health Interview Survey used a question 'Do you currently smoke cigarettes, cigars, pipe?' Thus, SAM estimated in this study reflects the harm from smoking various tobacco products, but does not include any estimated harm from second-hand exposure. Calculation of the second-hand smoking contribution to mortality would improve estimations using this method of the real burden of tobacco use.
The third limitation of the study was the use of RRs based on data from studies carried outside of Lithuania. Therefore probable country specific contributing environmental or genetic factors are automatically excluded. Limitations of using US-based RRs have been noted by other authors 10, 17 and apply to our study as well. One of the main strength of this study is the use of the 2013 Update to SAMMEC methodology published in The 2014 US Surgeon General Report. SAMMEC is a software created by the Centre for Disease and Prevention that defines SRDs and RRs-two elements crucial for SAM estimation. Method has been used in many countries including all states of the USA, Canada, Mexico, Germany, Italy, Spain, Brazil, Israel, Taiwan, Portugal. 10, 17 SAMMEC updates were recommended by an expert panel convened by the Centre for Disease and Prevention in 2009-10. 22 The 2014 US Surgeon General Report showed that now there is sufficient evidence to infer a causal relationship between smoking and five additional diseases in adults: age related macular degeneration, diabetes mellitus, tuberculosis, liver cancer and colorectal cancer. All diseases except age related macular degeneration were included in our estimations, making total of 26 causes of death.
The health effects of smoking result from many years of exposure, because an induction time is needed for tobacco to cause harm. The standard SAMMEC approach does not consider the latency period and this is pointed out as methodological weakness by several authors. 9 However, many authors have taken this into account and a time lagged prevalence approach is used more frequently. 10 We applied 8 years lag time for all smoking diseases, because of the availability of quality data for this time frame. Absence of historical series of smoking prevalence in most countries and the lack of knowledge of the latency and induction times for each of the tobacco related causes of death, determining time lag remains serious limitations for all studies using prevalence-based method. 9 Previously SAM in Lithuania was calculated only by using SIR method 5, 23 and hybrid method used by the Institute for Health Metrics (IHME) for the Global Burden of Disease Study (GBD). 24 SIR method that is also defined as an indirect method of estimating SAM is widely used for global estimations, since it requires less data than other methods. Authors of SIR method postulate that lung cancer mortality is an indicator of the maturity of the smoking epidemic in a population and SAM can be estimated by lung cancer mortality independently of the prevalence of smoking in the country. Sensitivity analysis using SIR method showed that estimates of the prevalence-based method tend to be higher, particularly for cardiovascular diseases among males (1.8 times higher number of SADs). The proportion of SADs from smoking related diseases (including fire related mortality) in 2013 was 37.3% with the prevalence-based method and 29.4% with the SIR method among male and 3.8 and 3.9%, respectively among female. The greatest difference between the two methods was found for cardiovascular diseases in men and respiratory disease and tuberculosis in women. However, both methods reveal large difference in results between male and female SAM. SADs in males were almost nine times higher than in females according to our base case analysis and almost seven times higher in the sensitivity analysis. Since absolute mortality from smoking related diseases was slightly higher in females (15 352) compared with men (13 887), huge gender differences in smoking burden can be explained by the significant gender differences in smoking prevalence in 2005. Difference between male and female smokers varied from 4 to 49 times in current smokers and from 4 to 10 times in former smokers groups. Overall no major differences in estimations using both methods were found and this replicates findings of other studies. 12, 25, 26 Hybrid method used for the GBD 2013 used lung cancer mortality as marker only for conditions with a long lag between exposure and outcome (such as cancers and chronic respiratory disease) and used 5 years lagged smoking prevalence applied to the CPS-II's RRs for all cardiovascular outcomes, tuberculosis, diabetes and asthma. 27 Our estimates for Lithuania in 2013 are higher: 13.9% (5771 SADs) in our base case analysis, compared with 12.3% (4803 SADs) of total mortality in the GBD 2013 study. 24 Overall, the GBD 2013 estimates are higher than our estimates with the SIR method, but lower than estimates from our base analysis. This shows that both prevalence and SIR-based methods, as well as hybrid method used by IHME offer comparable approximation of the burden of smoking.
Despite several methodological differences, our estimates of the base case analysis (i.e. 13.9% of total mortality attributable to smoking in 2013) are comparable to estimates of smoking attributed mortality in other European countries: 11.7% of total mortality in Portugal (2008), 28 12.5% in Italy (2010), 29 15 ,2% in Spain (2012). 30 Over the last two decades, overall smoking prevalence in Lithuania declined, however the trends were gender specific. Smoking among men declined from 44% in 1994-33% in 2014, while it increased from 7 to 12% in women. And while between 2006 and 2014 smoking among men declined by 11%, it only did so, by 3% in women. 31 Taking into consideration such differences in prevalence trends and decline in overall mortality by 4.6% between 2005 and 2015, 32 it is unlikely we can predict significant changes of SAM among women, but fewer deaths could be caused by smoking in men.
In regards to tobacco policy situation in Lithuania, significant positive policy developments were achieved. 33 Since 33 According to the ranking of the Tobacco Control Scale 2013 in Europe, 34 main weaknesses of the tobacco control in Lithuania are low tobacco product prices, limited treatment availability and low tobacco control budget (spending per capita by the government). Hence there is still an urgent need for an effective national tobacco control programme especially focusing on improving cessation help among current smokers. Besides, estimated smoking burden among men is significantly higher than in women, therefore need for gender specific interventions targeting male smokers in Lithuania should be investigated.
Despite various limitations that were discussed in this paper, our estimates provide public health experts and decision makers with a better understanding of mortality related burden imposed on society by smoking in Lithuania. It is further hoped that estimation of SAM and highlighted importance of tobacco impact on population mortality, would strengthen political resolve to address this harm by improving policies aimed at reduction of tobacco consumption. Of course there is a continued need for more comprehensive and routine estimation of SAM, morbidity and healthcare expenditures, including direct and indirect costs for both active and second-hand smoking.
Moreover prevalence-based analysis could be more often used to calculate and compare mortality associated with other risk factors and health conditions in Lithuania. For instance, globally this method is used to estimate mortality associated with illicit drugs, obesity, oral contraceptive use, hypertension, cardiovascular disorders and diabetes. 9 Conflicts of interest: None declared.
Key points
Smoking caused one out of seven deaths in Lithuania, one out of 35 female and one out of four male deaths. This corresponds to 13.9% of the total all cause deaths.
Both, prevalence based and smoking impact ratio-based methods offer comparable approximation of the burden of smoking despite their limitations.
Despite significant progress in tobacco control since 1996, further effective and comprehensive actions decreasing tobacco use need to be implemented. These include renewal of State Tobacco Control Programme and better implementation of existing national and European Union laws as well as the World Health Organization Framework Convention on Tobacco Control Articles and Protocols.
